Posted by Cort Johnson Norwegian journalist Jorgen Jelstad has been all over the Rituximab story. His Invest in ME Conference tweets updated us on recent events, in his “How Important is Rituximab?” blog he talked with researchers about Rituximab’s potential and in his recently blog, “The Drug”, he published a blow-by-blow account of how Rituximab grew to such prominence in the
ContinuePosted by Cort Johnson Could chronic fatigue syndrome be an autoimmune disorder? The Fluge/Mella Rituximab study was effective in at least temporarily reducing the symptoms of about 60% of the chronic fatigue syndrome patients in the study – a fact that no doubt shocked many who considered CFS purely a neuropsychiatric disorder. Rituximab started out as a chemotherapy drug but
ContinuePosted by Cort Johnson It doesn’t always take a village; sometimes it just takes a committed few to possibly change the future of a disorder; in this case, it may come down to just thirty patients and two researchers in Norway. The news that 2/3rds of CFS patients taking a chemotherapy drug called Rituximab significantly improved in a rigorous, double-blinded
Continue